TORONTO, July 26,
2024 /CNW/ - The National Advisory Committee on
Immunization's (NACI) annual Statement on Seasonal Influenza
Vaccines for 2024-2025 continues to recommend
Fluzone® High-Dose Quadrivalent among the
preferential influenza vaccines, over standard dose influenza
vaccines, to protect adults 65 years of age and older against
influenza. According to NACI, Fluzone® High-Dose
Quadrivalent has the most substantial body of supporting evidence
among preferentially recommended vaccines for adults 65 years of
age and older.i
Delphine
Lansac
General Manager, Vaccines Canada,
Sanofi
"More than one out of two seniors in
Canada who received a flu shot
were immunized with Fluzone® High-Dose this
past flu season. Fluzone® High-Dose has a
longstanding and consistent body of clinical evidence supporting
its benefits to protect adults 65 years and older from influenza
and reduce the risk of its potentially severe complications. As a
leader in public health protection in Canada, with roots dating back 110 years, we
are proud to soon be manufacturing Fluzone®
High-Dose right here in Toronto."
Dr. Angel
Chu MD, FRCPC
Infectious disease specialist,
Clinical Assistant Professor, University of
Calgary, STI Clinic Calgary, and Vice-Chair of Immunize
Canada
"In the newest NACI statement,
Fluzone® High-Dose continues to be recommended for
adults 65 years of age and older. NACI also recognizes
Fluzone® High-Dose has the most substantial body of
supporting evidence among flu vaccines for seniors."
Influenza can cause mild to severe illness, including
approximately 12,000 hospitalizations and 3,500 deaths annually in
Canadaii. Some
populations, especially young children and adults 65 years of age
and older, are at a higher risk for serious influenza
complicationsiii. Vaccination is the most effective way
to prevent influenza and its complicationsiv.
Fluzone® High-Dose Quadrivalent Influenza Vaccine is
specifically designed to provide protection for adults 65 years of
age and older with 4 times the active component dosage of a
standard vaccine. To date, Fluzone® High-Dose is
available in more than 20 countries including the US, Canada, and Germany and continues to be publicly funded in
Canada by numerous provinces and
territories.
Fluzone® High-Dose Quadrivalent Influenza Vaccine
will transition to a trivalent formulation for the 2025-2026
influenza season. The timing of this transition is also in line
with the recommendation of European health authorities. This is
following the direction of the World Health Organization to exclude
the B/Yamagata lineage from influenza vaccine formulations due to
the absence of confirmed detection of naturally occurring
B/Yamagata lineage viruses since March
2020. The benefits of annual influenza vaccination remain
unchanged, whether trivalent or quadrivalent. There are no safety
issues associated with the continued use of quadrivalent flu
vaccines for all populations globally.
Sanofi is a committed public health partner providing
life-saving vaccines and immunizations for Canadians and people
worldwide. As a global leader in influenza vaccine development and
manufacturing, we have met increasing demand for doses
of both Fluzone® Standard-Dose and High-Dose
vaccines over the past 4 years. Our footprint in
Canada continues to grow with two
new vaccine manufacturing facilities in Toronto. This includes the country's largest
pediatric and booster vaccine manufacturing facility, now open, and
a second facility that will produce
Fluzone® High-Dose.
About Sanofi
We are an innovative global healthcare company, driven by one
purpose: we chase the miracles of science to improve people's
lives. Our team, across the world, is dedicated to transforming the
practice of medicine by working to turn the impossible into the
possible. We provide potentially life-changing treatment options
and life-saving vaccine protection to millions of people globally,
while putting sustainability and social responsibility at the
center of our ambitions.
In Canada, we employ over 2,000 people. We invest 20% of our
revenue annually in biopharma research (representing $1.2 billion CAD in R&D investment over the
last decade) creating jobs, business, and opportunities throughout
the country. We are also on track to deliver over $2 billion CAD in new infrastructure investments
by 2028.
In 2024, we are celebrating 110 years of heritage dedicated to
developing innovative health solutions for Canadians. What started
as a small laboratory in May of 1914, recognized for having
advanced some of the greatest contributions to public health, both
nationally and globally, has evolved to become the largest
biomanufacturing facility in Canada.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
_____________________
|
i National Advisory Committee on
Immunization. An Advisory Committee Statement on Seasonal Influenza
Vaccines for 2024-2025. Date accessed 26 July 2024. Statement on
seasonal influenza vaccine for 2024–2025 - Canada.ca
|
|
ii National
Advisory Committee on Immunization. An Advisory Committee Statement
on Seasonal Influenza Vaccines for 2024-2025. Date accessed 26 July
2024. Statement on seasonal influenza vaccine for 2024–2025 -
Canada.ca
|
|
iii National
Advisory Committee on Immunization. An Advisory Committee Statement
on Seasonal Influenza Vaccines for 2024-2025. Date accessed 26 July
2024. Statement on seasonal influenza vaccine for 2024–2025 -
Canada.ca
|
|
iv National Advisory Committee on
Immunization. An Advisory Committee Statement on Seasonal Influenza
Vaccines for 2024-2025. Date accessed 26 July 2024. Statement on
seasonal influenza vaccine for 2024–2025 - Canada.ca
|
SOURCE SANOFI